BTLA-binding antibodies for modulating immune response and treating disease
US11384146B2 · kind B2 · utility
0Cited by
2References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 31, 2020 |
| Grant date | Jul 12, 2022 |
| Priority date | — |
| Expiry date | Mar 31, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/76
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides novel anti-BTLA antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer or autoimmune disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.